These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

639 related articles for article (PubMed ID: 28696585)

  • 1. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
    Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
    Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease.
    Mouzaki M; Wang AY; Bandsma R; Comelli EM; Arendt BM; Zhang L; Fung S; Fischer SE; McGilvray IG; Allard JP
    PLoS One; 2016; 11(5):e0151829. PubMed ID: 27203081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between circulating bile acid alterations and nonalcoholic steatohepatitis independent of obesity and diabetes mellitus.
    Jung Y; Koo BK; Jang SY; Kim D; Lee H; Lee DH; Joo SK; Jung YJ; Park JH; Yoo T; Choi M; Lee MK; Kang SW; Chang MS; Kim W; Hwang GS;
    Liver Int; 2021 Dec; 41(12):2892-2902. PubMed ID: 34358397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis.
    Chen J; Zheng M; Liu J; Luo Y; Yang W; Yang J; Liu J; Zhou J; Xu C; Zhao F; Su M; Zang S; Shi J;
    Obesity (Silver Spring); 2019 Dec; 27(12):2055-2066. PubMed ID: 31657148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis.
    Bechmann LP; Kocabayoglu P; Sowa JP; Sydor S; Best J; Schlattjan M; Beilfuss A; Schmitt J; Hannivoort RA; Kilicarslan A; Rust C; Berr F; Tschopp O; Gerken G; Friedman SL; Geier A; Canbay A
    Hepatology; 2013 Apr; 57(4):1394-406. PubMed ID: 23299969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
    Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
    JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC.
    Sydor S; Best J; Messerschmidt I; Manka P; Vilchez-Vargas R; Brodesser S; Lucas C; Wegehaupt A; Wenning C; Aßmuth S; Hohenester S; Link A; Faber KN; Moshage H; Cubero FJ; Friedman SL; Gerken G; Trauner M; Canbay A; Bechmann LP
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00131. PubMed ID: 32352707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease.
    Jahnel J; Zöhrer E; Alisi A; Ferrari F; Ceccarelli S; De Vito R; Scharnagl H; Stojakovic T; Fauler G; Trauner M; Nobili V
    J Pediatr Gastroenterol Nutr; 2015 Jul; 61(1):85-90. PubMed ID: 25729888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
    Ferslew BC; Xie G; Johnston CK; Su M; Stewart PW; Jia W; Brouwer KL; Barritt AS
    Dig Dis Sci; 2015 Nov; 60(11):3318-28. PubMed ID: 26138654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LC-MS-based lipidomic analysis in distinguishing patients with nonalcoholic steatohepatitis from nonalcoholic fatty liver.
    Wang ZH; Zheng KI; Wang XD; Qiao J; Li YY; Zhang L; Zheng MH; Wu J
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):452-459. PubMed ID: 34256994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ectodysplasin A Is Increased in Non-Alcoholic Fatty Liver Disease, But Is Not Associated With Type 2 Diabetes.
    Bayliss J; Ooi GJ; De Nardo W; Shah YJH; Montgomery MK; McLean C; Kemp W; Roberts SK; Brown WA; Burton PR; Watt MJ
    Front Endocrinol (Lausanne); 2021; 12():642432. PubMed ID: 33746906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
    Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
    Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bile acids associate with specific gut microbiota, low-level alcohol consumption and liver fibrosis in patients with non-alcoholic fatty liver disease.
    Adams LA; Wang Z; Liddle C; Melton PE; Ariff A; Chandraratna H; Tan J; Ching H; Coulter S; de Boer B; Christophersen CT; O'Sullivan TA; Morrison M; Jeffrey GP
    Liver Int; 2020 Jun; 40(6):1356-1365. PubMed ID: 32243703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.
    Legry V; Francque S; Haas JT; Verrijken A; Caron S; Chávez-Talavera O; Vallez E; Vonghia L; Dirinck E; Verhaegen A; Kouach M; Lestavel S; Lefebvre P; Van Gaal L; Tailleux A; Paumelle R; Staels B
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3783-3794. PubMed ID: 28938455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.